Gilead Sciences, Inc. (GILD) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 1:20 PM EDT
Company Participants
Daniel O’Day – Chairman & CEO
Andrew Dickinson – Executive VP & CFO
Presentation
Unknown Analyst
Good afternoon, everyone. Thank you so much for joining us. It’s my pleasure to introduce the Gilead team. We have Dan O’Day, Chairman and Chief Executive Officer; and Andy Dickinson, Chief Financial Officer.
Question-and-Answer Session
Unknown Analyst
To start here, Dan and Andy, perhaps give us an overview of where the company stands today, including your core franchises and how you’re thinking about priorities, outlook and strategy as we head into second half of the — or the year and beyond.
Daniel O’Day
Chairman & CEO
Sure. I’ll start, and Andy and I can tag team on it. But first of all, thanks for having us here. And we’ve been talking at this conference for a while now. I would say this is a really important time for Gilead. It’s really just watching our strategy play out over the past 7 years.
And what that means is kind of consistent commercial clinical execution, and we have the most robust pipeline that we’ve ever had in Gilead’s history. And I say that with a lot of admiration for the people that were at Gilead before I was. But — and what that means is we’ve got 3 really strong therapeutic areas.
Virology, never been stronger in terms of HIV. We just launched Hepcludex now for hepatitis B. But HIV, the long-acting programs, I know we’ll talk about that in both treatment and PrEP, Including kind of near-term issues that are occurring. We expect BIC/LEN to be launched soon, which is a terrific opportunity to take advantage of the switch market that occurs in HIV treatment with really novel integrase and capsid inhibitor.





You must be logged in to post a comment Login